To date, Qilu has launched over 300 products with over 50 products “First-to- launch” in China. The company has also fostered a robust pipeline including over 200 generic products, over 30 biosimilars and over 80 innovative products.
FINISHED DOSAGE FORMSLeading injectable and solid dose manufacturer with significant in-house development and manufacturing capabilities.Click to view +
ACTIVE PHARMACEUTICAL INGREDIENTSEquipped with large-scale manufacturing facilities for the production of chemically synthesized, lyophilized, sterile, crystallized and fermented APIs.Click to view +
Originated from QILU, Universal love to the WORLD
Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 30,000 employees worldwide, 70% of whom are with bachelor’s degree or above. It ranks No.10 in Chinese pharmaceutical industry by sales revenue in 2021. Dedicated to offering more affordable medicines to the world and improving people's well-being, Qilu has exported its products to over 90 countries.
Qilu Pharmaceutical has always maintained an innovative development strategy guided by the market demand and is achieving its organic growth strategy utilizing a strong pool of over 3,000 scientists spread across 5 R&D platforms based in the US (Seattle WA, Boston MA, San Francisco CA) and China (Shanghai, Jinan). To date, Qilu has launched over 200 products with over 50 products “First to launch” in China and 3 products “D181 launch”in US. The company has also a robust pipeline, including over 200 generic products, over 30 biosimilar products and over 80 innovative products.EXPLORE MORE >>
Domestic Manufacturing Sites
Chinese Pharma. & Industrial Enterprise
R & D